U.S. stock market midday update: Synlogic up 10.68%, delisting risk intertwined with financial benefits, how is market sentiment?

U.S. Stock Market Midday Update

Synlogic rose 10.68%. Based on recent key news:

1. On January 20, Synlogic received a delisting notice from Nasdaq, increasing market uncertainty. This news drew investor attention, and although the stock price rose, the delisting risk may affect the confidence of long-term investors.

2. On January 20, Synlogic released its latest financial information through the EDGAR system, showing the company's continued development in the biotechnology field. This information enhanced market confidence in its technological potential, driving the stock price up.

3. Recent trading volume has significantly increased, indicating rising investor interest in Synlogic. Increased trading volume typically suggests heightened market attention on the stock, further pushing the stock price up. The biotechnology industry has been active recently, with noticeable capital inflows.

Stocks with High Trading Volume in the Industry

AbbVie rose 0.95%. Based on recent key news:

1. On January 21, AbbVie’s technical route adjustment in the self-immune ADC field released industry signals, driving the stock price up. The efficacy logic of self-immune ADC has been confirmed, and it is expected to achieve sustained deep relief, attracting investor attention.

2. On January 21, Bernstein analysts maintained a hold rating on AbbVie and set a target price of $225. The stability of the analyst rating has enhanced market confidence, supporting the stock price increase.

3. On January 19, market analysis showed that AbbVie was not included in the list of five stocks recommended by top analysts; nevertheless, AbbVie still received a moderate buy rating, indicating market recognition of its long-term potential. Competition in the self-immune ADC field is intensifying, raising risk awareness.

Amgen rose 3.55%. Based on recent key news:

1. On January 21, Bernstein downgraded Amgen's rating to market perform, believing that 2026 may be a year of waiting, with the stock price fluctuating within 15% of the target price of $335. This rating adjustment may affect investor confidence, leading to stock price volatility.

2. On January 20, Piper Sandler analyst David Amsellem reiterated a buy rating on Amgen and set a target price of $381. This positive rating may boost market confidence in Amgen, driving the stock price up.

3. On January 20, Amgen's GLP-1 drug MariTide entered Phase 3 studies, covering various indications such as diabetes and weight management. This research and development progress may enhance market expectations for Amgen's future growth, supporting the stock price increase. The pharmaceutical industry faces patent cliff risks.

Moderna rose 13.44%. Based on recent key news:

1. On January 20, Moderna and Merck jointly disclosed five-year follow-up data from a Phase 2 clinical trial of the mRNA tumor vaccine mRNA-4157 combined with Keytruda, showing significant improvement in primary endpoints, driving the stock price up. According to Reuters, the vaccine reduced the risk of recurrence or death in melanoma patients by 49%, which enhanced market confidence in Moderna's innovation capabilities

2. On January 21, William Blair analysts pointed out that the five-year data update for intismeran shows significant advantages over Keytruda monotherapy in the postoperative setting, further solidifying Moderna's market position. Benzinga Pro data shows that Moderna's stock price rose by 2.8%, reaching $43.

3. On January 22, the innovative potential of the pharmaceutical industry attracted investor attention, with Moderna becoming the best-performing pharmaceutical stock in the S&P 500. According to Benzinga, Moderna's mRNA cancer therapy in collaboration with Merck drove the stock price up, demonstrating strong market momentum. The innovative potential of the pharmaceutical industry attracts investor attention.

Top Stocks by Market Capitalization in the Industry

Gilead Sciences rose by 3.66%. Based on recent news,

1. On January 20, analysts indicated that Gilead Sciences' anito-cel is expected to enter the market for second-line to fourth-line treatments based on MRD-negative results. Jefferies believes this is a clear positive for the company, although they think it will not change the overall landscape.

2. On January 20, Gilead Sciences was not included in the list of five best stocks recommended by analysts. Nevertheless, Gilead Sciences currently still holds a moderate buy rating among analysts.

3. On January 21, Jefferies pointed out that Legend's CARTITUDE-6 trial design includes MRD-negative as an endpoint, which has competitive implications for Gilead Sciences' anito-cel. Market trading is active, with significant capital inflow